Nishimura, Nobuko et al. published their research in Journal of Medicinal Chemistry in 2011 | CAS: 5912-35-6

6-Amino-8-bromo-1,7-naphthyridine (cas: 5912-35-6) belongs to naphthyridine derivatives. Functionalized naphthyridines and their benzo/heterofused analogs are present in numerous marine products and reported to possess wide-ranging activities such as antiproliferative, antiaggressive, and HIV-1 integrase inhibition in addition to their use as anti-HCV agents. Imidazonaphthyridines have been prepared through a ‘one-pot’ three-component ‘domino’ reaction between the keto-ester, acrolein, and ethylenediamine in presence of 4 Å molecular sieves.Recommanded Product: 6-Amino-8-bromo-1,7-naphthyridine

Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives was written by Nishimura, Nobuko;Siegmund, Aaron;Liu, Longbin;Yang, Kevin;Bryan, Marian C.;Andrews, Kristin L.;Bo, Yunxin;Booker, Shon K.;Caenepeel, Sean;Freeman, Daniel;Liao, Hongyu;McCarter, John;Mullady, Erin L.;San Miguel, Tisha;Subramanian, Raju;Tamayo, Nuria;Wang, Ling;Whittington, Douglas A.;Zalameda, Leeanne;Zhang, Nancy;Hughes, Paul E.;Norman, Mark H.. And the article was included in Journal of Medicinal Chemistry in 2011.Recommanded Product: 6-Amino-8-bromo-1,7-naphthyridine This article mentions the following:

The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3′-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound In the experiment, the researchers used many compounds, for example, 6-Amino-8-bromo-1,7-naphthyridine (cas: 5912-35-6Recommanded Product: 6-Amino-8-bromo-1,7-naphthyridine).

6-Amino-8-bromo-1,7-naphthyridine (cas: 5912-35-6) belongs to naphthyridine derivatives. Functionalized naphthyridines and their benzo/heterofused analogs are present in numerous marine products and reported to possess wide-ranging activities such as antiproliferative, antiaggressive, and HIV-1 integrase inhibition in addition to their use as anti-HCV agents. Imidazonaphthyridines have been prepared through a ‘one-pot’ three-component ‘domino’ reaction between the keto-ester, acrolein, and ethylenediamine in presence of 4 Å molecular sieves.Recommanded Product: 6-Amino-8-bromo-1,7-naphthyridine

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem